Klotho (alphaKlothoLR) (20mcg)

Klotho, specifically the alpha-Klotho variant (often abbreviated as αKlotho), is a protein primarily produced in the kidneys, brain, and other tissues. It’s named after the Greek Fate who spins the thread of life, due to its strong links to longevity and anti-aging. The “alphaKlothoLR” likely refers to a long-acting recombinant or lipidated form (e.g., alphaKlotho Long-Acting Recombinant), engineered for extended half-life and better bioavailability compared to native Klotho. At 20 mcg (micrograms), this appears to be a research-grade or experimental dose, commonly seen in preclinical studies or biohacking/supplement contexts—not an FDA-approved therapeutic.

Key Biological Roles (Backed by Science)

Klotho acts as a hormone-like regulator with these evidence-based effects:

• Anti-Aging & Lifespan Extension:
  • Suppresses insulin/IGF-1 signaling (mimicking caloric restriction).
  • Studies in mice (e.g., Nature 2003; Kuro-o et al.) show Klotho overexpression extends lifespan by 20-30% via reduced oxidative stress and inflammation.
  • Human correlations: Low serum Klotho levels predict shorter lifespan and age-related diseases (JAMA 2014 meta-analysis).
• Kidney & Cardiovascular Protection:
  • Inhibits vascular calcification and fibrosis (key in CKD; Science 2004).
  • Reduces blood pressure by modulating FGF23 (fibroblast growth factor 23) signaling.
• Neuroprotection:
  • Enhances cognition, synaptic plasticity, and reduces amyloid-beta in Alzheimer’s models (Cell Reports 2014).
  • Protects against stroke and neurodegeneration (JCI 2010).
• Metabolic Benefits:
  • Improves insulin sensitivity, reduces fat accumulation (PNAS 2006).
  • Potential in obesity/diabetes via TRPC channels.

Dose Context (20 mcg):

• Rodent studies use 0.1-1 mcg/kg IV/IP; human-equivalent for 70kg adult ~1-7 mcg total, so 20 mcg is on the higher end for subcutaneous/intravenous research dosing.
• Long-acting forms (e.g., LR = Long Release) like those from biotech firms (e.g., Unity Biotech or KLOTHO Therapeutics) aim for weekly/monthly dosing.

Potential Benefits at 20 mcg (Hypothetical/Research-Based)

Risks & Side Effects

• Generally Safe in Studies: No major toxicity in rodents/humans at low doses; half-life ~hours (native) to days (LR).
• Known Issues:
  • Hyperkalemia or electrolyte shifts (FGF23 modulation).
  • Hypotension in high doses.
  • Unknown long-term in humans (not approved).
• Sourcing Concerns: Often sold as “research peptides” (e.g., from Limitless Biotech or Peptide Sciences). Purity varies—third-party testing (HPLC/MS) essential to avoid contaminants.

How to Use (If Researching)

• Administration: SubQ (subcutaneous) or IV; 20 mcg weekly/biweekly for LR forms.
• Stacking: Often with NMN/NR (NAD+ boosters) or FGF21 analogs for synergy.
• Monitoring: Track kidney function (eGFR, creatinine), electrolytes, IGF-1 levels.

Legal/Availability: Research chemical only (not for human use per labels). Clinical trials (e.g., NCT05630820 for CKD) use similar doses. Consult a physician—not medical advice.

Sources: PubMed (search “alpha-Klotho aging”), Nature Reviews Endocrinology 2022 review. For latest trials: ClinicalTrials.gov.